论文部分内容阅读
近10年先后批准了6个新药用于治疗晚期大肠癌,包括伊立替康、卡培他滨、奥沙利铂、贝伐单抗、西妥昔单抗和帕妥尼单抗,新的治疗方案也不断涌现。与单用氟尿嘧啶一样,晚期大肠癌患者同样可从这3个细胞毒药物和3个靶向药物中获益。大量研究证实,随着这些新的药物和方案的应用,晚期大肠癌的中位生存期可以从最好支持治疗的6～8个月延长到联合化疗加靶向药物的30个月以上。本文试对晚期大肠癌化学治疗的新进展进行一个综述性评价。
Nearly 10 years have approved 6 new drugs for the treatment of advanced colorectal cancer, including irinotecan, capecitabine, oxaliplatin, bevacizumab, cetuximab and pituitrin, the new Treatment options are also emerging. As with fluorouracil alone, patients with advanced colorectal cancer also benefit from these 3 cytotoxic drugs and 3 targeted drugs. Numerous studies have confirmed that with these new drugs and programs, the median survival of advanced colorectal cancer can be extended from the best supportive treatment of 6 to 8 months to the combination of chemotherapy and targeted drugs for more than 30 months. This article attempts to evaluate the new progress of chemotherapy for advanced colorectal cancer.